Home Biosimilar Antibodies Immunology & Inflammation Interleukins Olokizumab (Anti-IL-6 / IFNb2)
For research use only. Not for use in humans.

Olokizumab (Anti-IL-6 / IFNb2)

Synonyms: CDP 6038

Olokizumab (Anti-IL-6 / IFNb2) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). It can be used in research of rheumatoid arthritis (RA). MW :145.4 KD.

Olokizumab (Anti-IL-6 / IFNb2)

Quality Control

Batch: A298501 Purity: 99% Protein concentration: 5.247mg/ml Endotoxin Level: ＜1EU/mg
99

Specificity

Name Citation IL-6 IL-1 IL-8 IL-12 IL-10 IL-13 IL-2 Others
SKF-86002 1
JTE-607 Dihydrochloride 2 TNF-alpha
A-740003 2 rat P2X7 receptor,human P2X7 receptor
Apilimod mesylate 6 PIKfyve
MD2-TLR4-IN-1 2 TLR4,TNF-α
Danirixin (GSK1325756) 2 CXCR2
Resatorvid (TAK-242) 65 TLR4,NO,TNF-α
Apilimod (STA-5326) 19 PIKfyve
LMT-28 1
Atractylodin 0 NAAA
Triolein 0 ROS,MMP-1
Ac-YVAD-cmk 5
Diethyl phosphate 1
RCM-1 5 STAT6,FOXM1,β-catenin
Stylopine 0 COX-2,TNF-α,NO
Myrislignan 1 NF-κB,COX-2,iNOS
NE 52-QQ57 2 iNOS,TNF-α,PGE2
PKR-IN-C16 9 PKR
(3R,8S)-Falcarindiol 3 STAT,ERK,JNK
Gardenoside 1 P2X7 Receptor,P2X3 receptor,NF-κB
T-5224 23 c-Jun,c-Fos/AP-1,Adamts-5
IQ 3 1 TNF-α,JNK3,JNK1
Isuzinaxib (APX-115 free base) 2 TNFα,MCP-1/CCL2,NOX2
AUDA 1 p38,Smad3,TGF-β
SAR-20347 1 IFN-α,TYK2,JAK1
SU 5201 0
Madecassic acid 3 TNF-α,COX-2,iNOS
Homoplantaginin 1 NF-κB,IKKβ,TNF-α
2',5'-Dihydroxyacetophenone 1 NF-κB,ERK1/2,iNOS
Forsythoside B 0 NF-κB,TNF-alpha,IκB
Mulberroside A 0 NF-κB,Caspase-1,NALP3
Chelidonic acid 0 glutamate decarboxylase,Caspase-1,NF-κB
4-Methylesculetin 2 MPO
Muscone 4 TNF-α,NLRP3 inflammasome,NF-κB
Ossirene (AS101) 16
Methylthiouracil 1 ERK1/2,NF-κB,TNF-α
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Olokizumab (Anti-IL-6 / IFNb2) is a humanized monoclonal antibody targeting the interleukin-6 (IL-6). It can be used in research of rheumatoid arthritis (RA). MW :145.4 KD.
References

Product Details

CAS No. 1007223-17-7
Molecular Weight 145.4
Isotype Human IgG4SP
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05305066 RECRUITING Drug: TNFi|Drug: Anti-IL6|Drug: JAKi Rheumatoid Arthritis Marie Hudson, MD 2023-02-01
NCT07625384 NOT_YET_RECRUITING Drug: Placebo Still Disease R-Pharm International, LLC 2026-05-18 PHASE3
NCT06440746 RECRUITING Drug: Subcutaneous (SC) injections of OKZ 64 milligrams (mg) Lung Diseases, Interstitial R-Pharm International, LLC 2023-08-23 PHASE2; PHASE3
NCT07517575 RECRUITING Drug: OKZ q4w|Drug: OKZ q4w Juvenile Idiopathic Arthritis R-Pharm International, LLC 2023-03-17 PHASE2
NCT05679570 COMPLETED Drug: Satralizumab (Genetical Recombination) Pulmonary Arterial Hypertension International University of Health and Welfare 2022-07-12 PHASE2
NCT07670546 ACTIVE_NOT_RECRUITING Drug: Placebo Polymyalgia Rheumatica R-Pharm International, LLC 2025-06-11 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-02-03)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.